Home » Gilead Sciences, Galapagos Halt Studies for Autotaxin Inhibitor
Gilead Sciences, Galapagos Halt Studies for Autotaxin Inhibitor
Gilead Sciences and Galapagos have decided to discontinue research on their investigational autotaxin inhibitor ziritaxestat, including a phase 3 program evaluating it as a treatment for idiopathic pulmonary fibrosis (IPF).
The phase 3 program includes two identically designed late-stage trials that sought to enroll a combined 1,500 IPF patients. But the companies have decided to end their research on ziritaxestat after a review of unblinded data concluded that the drug had an unacceptable benefit-risk profile.
The companies are also discontinuing the long-term extension of their phase 2a trial evaluating the autotaxin inhibitor as a systemic sclerosis treatment.
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May